Last reviewed · How we verify
Coriogonadotropin alfa
Coriogonadotropin alfa is a Gonadotropin; hCG analog Small molecule drug developed by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. It is currently in Phase 3 development for Luteal phase support in assisted reproductive technology (ART) / in vitro fertilization (IVF). Also known as: r-hCG.
Coriogonadotropin alfa is a recombinant human chorionic gonadotropin (hCG) analog that stimulates the corpus luteum to produce progesterone for luteal phase support in assisted reproductive technology.
Coriogonadotropin alfa is a recombinant human chorionic gonadotropin (hCG) analog that stimulates the corpus luteum to produce progesterone for luteal phase support in assisted reproductive technology. Used for Luteal phase support in assisted reproductive technology (ART) / in vitro fertilization (IVF).
At a glance
| Generic name | Coriogonadotropin alfa |
|---|---|
| Also known as | r-hCG |
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Drug class | Gonadotropin; hCG analog |
| Target | Luteinizing hormone/chorionic gonadotropin receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | Phase 3 |
Mechanism of action
This drug mimics the natural hormone hCG, which is produced after embryo implantation to maintain the corpus luteum and ensure adequate progesterone secretion during early pregnancy. By providing exogenous hCG support during the luteal phase following ovarian stimulation and embryo transfer, it enhances endometrial receptivity and reduces miscarriage risk in fertility treatments. The recombinant formulation offers a consistent, pure alternative to urinary-derived hCG.
Approved indications
- Luteal phase support in assisted reproductive technology (ART) / in vitro fertilization (IVF)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Headache
- Abdominal pain/discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coriogonadotropin alfa CI brief — competitive landscape report
- Coriogonadotropin alfa updates RSS · CI watch RSS
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany portfolio CI
Frequently asked questions about Coriogonadotropin alfa
What is Coriogonadotropin alfa?
How does Coriogonadotropin alfa work?
What is Coriogonadotropin alfa used for?
Who makes Coriogonadotropin alfa?
Is Coriogonadotropin alfa also known as anything else?
What drug class is Coriogonadotropin alfa in?
What development phase is Coriogonadotropin alfa in?
What are the side effects of Coriogonadotropin alfa?
What does Coriogonadotropin alfa target?
Related
- Drug class: All Gonadotropin; hCG analog drugs
- Target: All drugs targeting Luteinizing hormone/chorionic gonadotropin receptor (LHCGR)
- Manufacturer: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany — full pipeline
- Therapeutic area: All drugs in Reproductive Medicine / Fertility
- Indication: Drugs for Luteal phase support in assisted reproductive technology (ART) / in vitro fertilization (IVF)
- Also known as: r-hCG